R&D 2018-04-19T16:05:32+00:00

Biosynex: the expertise

The historical technological expertise of BIOSYNEX is focused on the development of rapid diagnostic tests based of the immunochromatography or immunofiltration principle using membrane supports (nitrocellulose).

These tests combine simplicity of execution, fast results acquisition and high level of clinical performances. These tests also combine easy transportation and preservation.

Biosynex’s development strategy is focused on niche products with high added-value and reduced competition. In this context, we have recently diversified our technological platforms in the fields of molecular biology, microbiology and parasitology.

Our goal is to develop innovative tests which respond to new medical issues and provide health professionals with immediate information that guides patient management.

In order to implement this strategy, we benefit from a high-level specific committee and a network of leading expert clinicians.

Today, BIOSYNEX focuses its expertise on point of care biology, a fast growing sector that aims to reduce healthcare costs and provide greater flexibility for healthcare professionals by providing them with immediate diagnostic information.

Three areas are mainly targeted:

  1. Infectious diseases, based on immunochromatography, agglutination or molecular biology techniques that can be carried out quickly and on an ad hoc basis.
  2. Obstetrics (premature fetal membrane rupture, premature delivery)
  3. Point of care biology, by developing connectable readers which can be used directly in clinical services and adapted to our rapid tests.

Biosynex: the R&D department

The BIOSYNEX’s R&D department is based in Strasbourg and employs a dozen scientists who benefit from a powerful technological platform and a broad experience in the specialized field of the in vitro diagnostics industry.

The company has developed industrial and academic partnerships to develop leading products.

For example, BIOSYNEX’s new Cryptococcosis test was developed in collaboration with the National Reference Center of the Institut Pasteur.

Since its creation, the development of BIOSYNEX has been supported by regional public aid (Alsace region), the French agency for innovation (OSEO or BpiFrance) and European programs (FTP7). Here are some examples of our projects supported by public aid:

  • DiagEBV project, certified by the Alsace Biovalley cluster, for the development of rapid tests for the detection of infections with the Epstein Barr virus (2008-2011)
  • “Dispositif Gradient” of the Alsace region to finance production’s automation (2012 to 2015)
  • FTP7 PIPAVIR project for the development of detection tests for oncoprotein E7 used as an evolutionary marker for papillomavirus infections (2012 to 2015)
  • Financing by BpiFrance for a project to develop innovative tests in the field of premature delivery (zero-rated loan agreement for innovation, 2015 to 2017)

BIOSYNEX already has several patents in the field of obstetrics, especially for its fetal membrane rupture detection test based on the detection of two biomarkers. BIOSYNEX holds a French patent (FR1054374) with a worldwide extension (WO2011 / 151597A1). A European grant of this patent (EP 2577317) in 2014 was followed in 2015 by an Australian issue.

BIOSYNEX is committed to being global and has adopted a proactive IP protection strategy.

Biosynex: the R&D department

The Biosynex R&D department based in Strasbourg employs a dozen scientists who benefit from a powerful technological platform and a vast experience in the specialized field of the in vitro diagnostics industry.

The company has developed industrial and academic partnerships to develop flagship products.

For example, Biosynex’s new Cryptococcosis test was developed in collaboration with the Institut Pasteur’s National Reference Center.

The development of Biosynex has been supported since its creation by regional public aid (Alsace region), the French agency for innovation (OSEO or BpiFrance) and European programs (FTP7). Here are some examples of our projects supported by public aid:

  • DiagEBV project certified by the Alsace Biovalley cluster for the development of rapid tests for the detection of infections with the Epstein Barr virus (2008-2011)
  • Gradient device of the Alsace region to finance an automation of production (2012 to 2015)
  • PIPAVIR FTP7 project for the development of detection tests for oncoprotein E7 used as an evolutionary marker for papillomavirus infections (2012 to 2015)
  • Funding by BpiFrance for a project to develop innovative tests in the field of prematurity (zero-rated loan agreement for innovation, 2015 to 2017)

Biosynex already has several patents in the field of obstetrics, notably for its fetal membrane rupture detection test based on the detection of two biomarkers.
Thus, Biosynex holds a French patent (FR1054374) with a worldwide extension (WO2011 / 151597A1). A European grant of this patent (EP 2577317) in 2014 was followed in 2015 by an Australian issue.

Biosynex is committed to being global and has adopted a proactive IP protection strategy.

test

test